Enlarge (credit: CNBC)

With rage surging over claims of price gouging, EpiPen manufacturer Mylan took a page from Turing’s playbook today. CEO Heather Bresch told CNBC that the company is taking “immediate action” to make the life-saving auto-injectors available to any patients that need one. The company will expand discounts and eligibility of its customer assistance program.

However, Mylan gave no sign that it will lower the EpiPen’s list price, which the company has hiked up more than 400 percent in recent years. Though an EpiPen only costs a few dollars to make and can reverse deadly allergic reactions, they now can cost more than $600.

Bresch, seen as the mastermind of the price hike and currently one of the highest paid executives in the industry, tried instead to shift the conversation to problems in the American healthcare system.